“Passive” Adverse Event Data Inadequate, Say FDA/HRS Meeting Panelists
This article was originally published in The Gray Sheet
Executive Summary
FDA must expand its "enhanced" adverse event reporting system and improve "passive" surveillance in order to detect rare device malfunctions, said panelists at the Policy Conference on Pacemaker and Implantable Cardioverter Defibrillator Performance in Washington, D.C. Sept. 16
You may also be interested in...
Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb
The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb
The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Physicians Implanting ICDs, Pacers Need Education On Reliability – HRS Docs
The Heart Rhythm Society should work with FDA and manufacturers to educate physicians on realistic expectations for ICD and pacemaker performance, according to participants at the Policy Conference on Pacemaker and ICD Performance